SG11202009872YA - Stable antibody formulation - Google Patents
Stable antibody formulationInfo
- Publication number
- SG11202009872YA SG11202009872YA SG11202009872YA SG11202009872YA SG11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA SG 11202009872Y A SG11202009872Y A SG 11202009872YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody formulation
- stable antibody
- stable
- formulation
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201841013645 | 2018-04-10 | ||
PCT/IN2019/050291 WO2019198099A1 (en) | 2018-04-10 | 2019-04-10 | Stable antibody formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202009872YA true SG11202009872YA (en) | 2020-11-27 |
Family
ID=68164052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202009872YA SG11202009872YA (en) | 2018-04-10 | 2019-04-10 | Stable antibody formulation |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210253714A1 (en) |
EP (1) | EP3773695A4 (en) |
JP (1) | JP2021521168A (en) |
CN (1) | CN112243379A (en) |
AU (1) | AU2019251452A1 (en) |
BR (1) | BR112020020741A2 (en) |
CO (1) | CO2020013545A2 (en) |
SG (1) | SG11202009872YA (en) |
WO (1) | WO2019198099A1 (en) |
ZA (1) | ZA202006262B (en) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA05008409A (en) * | 2003-02-10 | 2005-10-05 | Elan Pharm Inc | Immunoglobulin formulation and method of preparation thereof. |
US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
RU2011140498A (en) * | 2009-03-06 | 2013-04-20 | Дженентек, Инк. | PREPARATION ANTIBODIES |
UA116189C2 (en) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | FORMULATION FOR ANTI-α4β7 ANTIBODY |
PE20141672A1 (en) * | 2011-05-02 | 2014-11-26 | Millennium Pharm Inc | FORMULATION FOR ANTI-alpha4�7 ANTIBODY |
CN112218654A (en) * | 2018-04-10 | 2021-01-12 | 雷迪博士实验室有限公司 | Antibody formulations |
CN112292146A (en) * | 2018-04-10 | 2021-01-29 | 雷迪博士实验室有限公司 | Stable formulations of therapeutic antibodies |
AR119268A1 (en) * | 2019-06-10 | 2021-12-09 | Millennium Pharm Inc | METHODS OF PURIFICATION OF ANTIBODIES AND THEIR COMPOSITIONS |
JP2022536486A (en) * | 2019-06-10 | 2022-08-17 | 武田薬品工業株式会社 | Method for producing anti-α4β7 antibody |
-
2019
- 2019-04-10 EP EP19785443.3A patent/EP3773695A4/en active Pending
- 2019-04-10 CN CN201980038032.1A patent/CN112243379A/en active Pending
- 2019-04-10 US US17/045,336 patent/US20210253714A1/en active Pending
- 2019-04-10 WO PCT/IN2019/050291 patent/WO2019198099A1/en unknown
- 2019-04-10 JP JP2020555449A patent/JP2021521168A/en active Pending
- 2019-04-10 SG SG11202009872YA patent/SG11202009872YA/en unknown
- 2019-04-10 AU AU2019251452A patent/AU2019251452A1/en not_active Abandoned
- 2019-04-10 BR BR112020020741-1A patent/BR112020020741A2/en not_active IP Right Cessation
-
2020
- 2020-10-08 ZA ZA2020/06262A patent/ZA202006262B/en unknown
- 2020-10-28 CO CONC2020/0013545A patent/CO2020013545A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20210253714A1 (en) | 2021-08-19 |
JP2021521168A (en) | 2021-08-26 |
WO2019198099A1 (en) | 2019-10-17 |
AU2019251452A2 (en) | 2020-12-03 |
CN112243379A (en) | 2021-01-19 |
ZA202006262B (en) | 2023-01-25 |
EP3773695A1 (en) | 2021-02-17 |
EP3773695A4 (en) | 2021-12-22 |
BR112020020741A2 (en) | 2021-01-19 |
CO2020013545A2 (en) | 2021-01-18 |
AU2019251452A1 (en) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL269499A (en) | Stable antibody formulation | |
IL281717A (en) | Antibody formulation | |
IL281255A (en) | Csf-1r antibody formulation | |
IL282813A (en) | Antibody formulation | |
IL282617A (en) | Aerosolisable formulation | |
GB201801614D0 (en) | Formulation | |
IL286100A (en) | Anti-il-36r antibody formulations | |
IL282523A (en) | Aerosolisable formulation | |
IL282567A (en) | Aerosolisable formulation | |
IL282589A (en) | Aerosolisable formulation | |
IL281976A (en) | Anti-fgfr2 antibody formulations | |
GB201816447D0 (en) | Formulation | |
ZA202006263B (en) | Antibody formulation | |
IL282461A (en) | Aerosolisable formulation | |
IL282697A (en) | Aerosolisable formulation | |
IL282392A (en) | Aerosolisable formulation | |
IL283886A (en) | Antibody formulations | |
GB201807312D0 (en) | Formulation | |
IL280138A (en) | Aerosolisable formulation | |
GB201813229D0 (en) | Formulation | |
ZA202006262B (en) | Stable antibody formulation | |
GB201817866D0 (en) | Aerosolisable formulation | |
GB201809575D0 (en) | Formulation | |
GB201804621D0 (en) | Formulation |